274 Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CART cell therapy with disruptions of the TGFBR2 and Regnase-1 genes for improved manufacturing and potency
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
DOI:
10.1136/jitc-2023-sitc2023.0274
Publication Date:
2023-10-31T13:48:37Z
AUTHORS (41)
ABSTRACT
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....